Are You Interested In Learning More?

We would like to introduce you to a new gout study being offered at the Bradenton Research Center. This study is being conducted to access the safety, tolerability and efficacy of Krystexxa/Methotrexate combination administered over a shorter infusion duration (30 minutes) for patients with uncontrolled gout (currently FDA approved for a two-hour infusion rate).

 

This is an open-label study where everyone will receive the study medication. Reimbursement for your time and travel is up to $1,600. We are currently setting up screening visits, but we are filling up fast.

 

Our staff is available to speak with you to answer any questions you may have about this study, or any of our other studies. To contact us directly, please fill out the form below. If you are eligible to participate, one of our study coordinators will contact you to schedule.

Please consider contacting us today, to see if you/they qualify.